

1 A comparison of four epidemic waves of 2 COVID-19 in Malawi; an observational 3 cohort study

4 Authors: Catherine Anscombe^{*1, 2}, Samantha Lissauer^{*1,4}, Herbert Thole^{*1}, Jamie Rylance^{1,2},
5 Dingase Dula¹, Mavis Menyere¹, Belson Kutambe¹, Charlotte van der Veer^{1,11}, Tamara Phiri⁹,
6 Ndazona P. Banda⁸, Kwazizira S. Mndolo⁹, Kelvin Mponda⁹, Chimota Phiri⁹, Jane Mallewa⁸,
7 Mulinda Nyirenda^{8,9}, Grace Katha⁹, Henry Mwandumba^{1,2,8}, Stephen B. Gordon^{1,2}, Kondwani C.
8 Jambo^{1,2,8}, Jennifer Cornick^{1,4}, Nicholas Feasey^{1,2}, Kayla G. Barnes^{+1,4,5,6,7}, Ben Morton^{+1,2,10},
9 Philip M. Ashton^{+&1,4}, Blantyre COVID-19 Consortium[%]

- 10 1. Malawi-Liverpool-Wellcome Clinical Research Programme, Kamuzu University of Health
11 Sciences, Blantyre, Malawi
- 12 2. Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United
13 Kingdom
- 14 3. Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom
- 15 4. Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool,
16 United Kingdom
- 17 5. Harvard School of Public Health, Boston, USA
- 18 6. Broad Institute of MIT and Harvard, Cambridge, USA
- 19 7. University of Glasgow MRC Centre for Virus Research, Glasgow, UK

20 8. Kamuzu University of Health Sciences (formerly University of Malawi-College of Medicine)

21 Blantyre, Malawi

22 9. Department of Medicine, Queen Elizabeth Central Hospital, Blantyre, Malawi

23 10. Liverpool University Hospitals Foundation Trust, Liverpool, UK.

24 11. Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom

25 * Contributed equally, + Contributed equally, & Corresponding authors, % Consortium

26 members are listed in the acknowledgement section.

27 Corresponding author: Philip Ashton (philip.ashton@liverpool.ac.uk)

28 Alternate corresponding author: Samantha Lissauer (Samantha.Lissauer@liverpool.ac.uk)

29 **Keywords**

30 COVID; SARS-CoV-2; ISARIC; Delta; mortality; LMIC; Malawi; Africa

31 **Summary**

32 We used genome sequencing to identify the variants of SARS-CoV-2 causing disease in Malawi,

33 and found that each of the four waves was caused by a distinct variant. Clinical investigation

34 suggested that the Delta wave had the highest mortality.

35 **Running title**

36 ISARIC COVID WGS

37 Abstract

38 Background

39 Compared to the abundance of clinical and genomic information available on patients
40 hospitalised with COVID-19 disease from high-income countries, there is a paucity of data from
41 low-income countries. Our aim was to explore the relationship between viral lineage and
42 patient outcome.

43 Methods

44 We enrolled a prospective observational cohort of adult patients hospitalised with PCR-
45 confirmed COVID-19 disease between July 2020 and March 2022 from Blantyre, Malawi,
46 covering four waves of SARS-CoV-2 infections. Clinical and diagnostic data were collected using
47 an adapted ISARIC clinical characterization protocol for COVID-19. SARS-CoV-2 isolates were
48 sequenced using the MinION™ in Blantyre.

49 Results

50 We enrolled 314 patients, good quality sequencing data was available for 55 patients. The
51 sequencing data showed that 8 of 11 participants recruited in wave one had B.1 infections, 6/6
52 in wave two had Beta, 25/26 in wave three had Delta and 11/12 in wave four had Omicron.
53 Patients infected during the Delta and Omicron waves reported fewer underlying chronic
54 conditions and a shorter time to presentation. Significantly fewer patients required oxygen

55 (22.7% [17/75] vs. 58.6% [140/239], $p < 0.001$) and steroids (38.7% [29/75] vs. 70.3% [167/239],
56 $p < 0.001$) in the Omicron wave compared with the other waves. Multivariable logistic-regression
57 demonstrated a trend toward increased mortality in the Delta wave (OR 4.99 [95% CI 1.0-25.0
58 $p = 0.05$) compared to the first wave of infection.

59 Conclusions

60 Our data show that each wave of patients hospitalised with SARS-CoV-2 was infected with a
61 distinct viral variant. The clinical data suggests that patients with severe COVID-19 disease were
62 more likely to die during the Delta wave.

63

64 Introduction

65 There is limited COVID-19 genomic surveillance data from low income countries such as Malawi
66 [1]. Genomic surveillance data supports the development of contextually relevant and effective
67 national, regional and international public health interventions [2]. For patients with severe
68 disease, little is known about the impact of viral variants on disease severity in these resource
69 constrained settings where there is frequently a high prevalence of concomitant HIV-infection.
70 Early data from South Africa suggested that the emergence of the SARS-CoV-2 omicron variant
71 of concern (VOC) was associated with reduced disease severity [3], but there is a paucity of data
72 from neighbouring countries in the region.

73
74 Genomic sequencing is a vital tool to inform strategies for an effective COVID-19 care and
75 treatment response. The early release of the Wuhan-1 genome sequence [4] enabled the
76 development of specific diagnostic tests [5] and the design of mRNA vaccines, used to great
77 success in high-income countries [6,7]. The evolution of the virus has led to the emergence of
78 lineages designated as VOCs, which are defined using genome sequencing and the widespread
79 use of genomic surveillance to inform public health strategy has been a defining feature of the
80 pandemic [8,9]. Early data on the emergence of VOCs has enabled policy makers to rapidly
81 implement public health responses to constrain disease spread; prepare health systems (e.g.
82 increased oxygen provision; opening more hospital beds; and increasing testing); and to select
83 optimal vaccines and therapies [10]. In Malawi, Blantyre is the commercial hub with high
84 detected rates of COVID-19 disease [11]. We previously deployed the WHO-accredited

85 International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) clinical
86 characterisation protocol at Queen Elizabeth Central Hospital (QECH) to patients admitted
87 with suspected COVID-19 disease [12]. However, this cohort completed in September 2020; and
88 did not include pathogen genome sequencing.

89
90 In this study we determined SARS-CoV-2 genome sequences from swabs collected from adult
91 patients admitted to Queen Elizabeth Central Hospital (QECH) with PCR-confirmed and
92 symptomatic COVID-19 during four sequential waves of the pandemic. Our aim was to explore
93 the relationship between viral lineage and patient outcome in southern Malawi using an
94 international clinical characterisation protocol. Based on emerging data from other settings
95 [13–16], we hypothesised that there would be increased disease severity for patients with
96 confirmed Delta disease.

97 Methods

98 Study design and recruitment

99 We prospectively recruited adult patients (>18 years old) using the tier one sampling strategy
100 from the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC)
101 Clinical Characterisation Protocol (CCP) [17], as previously described [12]. Patients were
102 recruited at Queen Elizabeth Central Hospital (QECH), Blantyre, Malawi, the largest referral
103 hospital in southern Malawi. For this study, only patients admitted to hospital with severe
104 acute respiratory infection and a positive SARS-CoV-2 PCR test (defined as a Ct <40) were
105 included. Patients (or personal consultee if the patient lacked capacity) with a severe acute
106 respiratory infection (SARI) were consecutively approached for informed consent with an aim to
107 recruit within 72 hours of hospital admission. Respiratory samples (combined nasopharyngeal
108 and oropharyngeal swab) and peripheral venous blood samples were collected at recruitment.
109 SARS-CoV-2 PCR diagnostic testing was carried out on the swab samples, as previously
110 described [12]. Waves (W) of SARS-CoV-2 were defined with reference to nationally reported
111 COVID-19 figures (W1: 04/2020 – 10/2020, W2: 11/2020 – 03/2021; W3: 04/2021 – 08/2021;
112 and W4: 12/2021 – 03/2022). COVID-19 vaccine became available in Malawi from 10th March
113 2021 [18].

114

115 During the recruitment period, patients with COVID-19 were treated on wards capable of
116 providing continuous oxygen therapy, but without capacity for invasive mechanical ventilation,

117 intensive care facilities, continuous positive airways pressure (CPAP) or high flow oxygen. All
118 patients received protocolised standard care depending on the severity, including oxygen,
119 steroids and antibiotics as previously described [19]. Clinical and treatment parameters were
120 recorded using the ISARIC standardised case report form. Participants were followed up until
121 death, discharge or transfer to another facility.

122

123 Study protocols were approved by the Malawi National Health Science Research Committee
124 (NHSRC, 20/02/2518 and 19/08/2246) and Liverpool School of Tropical Medicine Research
125 Ethics Committee (LSTM REC, 20/026 and 19/017). We have included a reflexivity statement
126 detailing how equitable partnership was promoted within our collaboration in the
127 Supplementary Material.

128 SARS-CoV-2 molecular biology and genome sequencing

129 Samples were extracted using the Qiasymphony-DSP mini kit 200 (Qiagen, UK) with offboard
130 lysis or manually using the Qiagen mini viral extraction kit. Samples were then tested using the
131 CDC N1 assay to confirm the Ct values before sequencing. ARTIC protocol V2 sequencing
132 protocol was used until June 2021, after which we switched to the V3 protocol. ARTIC version 3
133 primers were used for the tiling PCR until we switched to the University of Zambia (UNZA)
134 primer set that provided better results for Delta VOC in August 2021 (data not shown) [20].
135 Initially two primer pools were used, however a third pool was made for primer pairs that
136 commonly had lower depth compared to the average (details Supplementary Table 1). PCR
137 cycling conditions were adapted to the new sequencing primers, with annealing temperature

138 changed to 60°C. Sequencing was carried out with the Oxford Nanopore Technologies MinION
139 sequencer. Samples that had poor coverage (<70%) with the ARTIC primer set were repeated
140 with the UNZA primer set.

141 Analysis of SARS-CoV-2 sequencing data

142 Raw FAST5 data produced by the MinION were processed with Guppy v5.0.7. FAST5s were
143 basecalled with guppy_basecaller, basecalled FASTQs were assigned to barcodes using
144 guppy_barcode, including the `--require_barcodes_both_ends` flag. The per-sample FASTQ
145 files were processed with the artic pipeline using the `medaka` option [21]. The lineage of each
146 consensus genome was identified using pangolin with the following versions; pangolin v3.1.17,
147 pangolearn 2021-12-06, constellations v0.1.1, scorpio v0.3.16, pango-designation used by
148 pangoLEARN/Usher v1.2.105, pango-designation aliases v1.2.122 [22]. Samples were re-
149 analysed when the Pangolin database was updated. The run was repeated if there was
150 contamination in the negative control.

151
152 To set reasonable Ct thresholds for selecting samples to sequence in future work, we plotted
153 the true positive rate versus the false positive rate (i.e. ROC curves) for a range of Ct thresholds
154 from 15 to 40, where the true positive rate was defined as the proportion of samples with a
155 genome coverage $\geq 70\%$ that had a Ct below the threshold. The false-positive rate was defined
156 as the proportion of samples with a genome coverage $< 70\%$ that had a Ct below the threshold.

157 Code to calculate the values for the ROC curves is available here -

158 <https://gist.github.com/flashton2003/bb690261106dc98bb1ae5de8a0e61199>. The

159 lineage/VOC of samples in GISAID was obtained via the GISAID website

160 (<https://www.epicov.org/epi3/start>).

161 Statistical analysis

162 Clinical data were analysed using Stata V15.1 (StataCorp, Stata Statistical Software: Release 15,

163 College Station, Texas, USA). Categorical variables were compared using Fisher's exact test.

164 Continuous variables were tested for normality and appropriate statistical tests were applied;

165 non-normally distributed measurements are expressed as the median [IQR] and were analysed

166 by the Kruskal-Wallis test to compare clinical parameters across the four waves. The primary

167 outcome variable was survival to hospital discharge. We selected the following covariates *a*

168 *priori* to determine potential predictors of mortality: pandemic infection wave; vaccine status;

169 age; sex; HIV infection status; prior diagnosis of cardiac disease; prior diagnosis of diabetes

170 mellitus; time from symptoms to hospital admission; respiratory rate; and oxygen saturation

171 (SpO₂). This information was obtained from the patients admission files, health passport,

172 medical chart or other documents. HIV was not independently confirmed, but was determined

173 from patient medical records. All the above variables were included within the multivariable

174 model and were collected at, or shortly after, hospital admission (selected as clinically relevant

175 parameters that could reasonably be used by clinicians to influence treatment decisions).

176 Univariable and multivariable logistic regression analyses were fitted using the STATA "logistic"

177 command to generate odds ratios and confidence intervals (see supplementary materials). In

178 addition, we conducted an exploratory sensitivity analysis, excluding patients who did require

179 supplemental oxygen (indicative of less severe disease) at the time of enrolment. The overall

180 statistical significance of the difference in mortality between waves was assessed using a
181 likelihood ratio test, comparing the univariable model against a null, intercept-only model and
182 the full multivariable model against a null model with all covariates except for the categorical
183 variable encoding the epidemic wave. Statistical analysis and plotting of genomic results was
184 done using R v4.1.0 [23]. Exact binomial confidence intervals for the proportion of each
185 genotype during each wave were calculated using the `binom.test` function. Statistical analysis
186 STATA code is available here
187 <https://gist.github.com/flashton2003/c241f1153a6a9cb76a26f5857fe53976>).

188

189 Results


190 Patient Recruitment and SARS-CoV-2 genomic analysis

191 Between July 2020 and March 2022, we recruited 314 adults with PCR confirmed COVID-19
192 disease, using the ISARIC Clinical Characterisation Protocol (Table 1). Recruitment spanned four
193 distinct waves of COVID-19 in Malawi; 1st wave n=48 (July-November 2020), 2nd wave n=94
194 (December 2020-March 2021), 3rd wave n=97 (June 2021-October 2021) and 4th wave n=75
195 (December 2021-March 2022). The higher number of participants recruited in waves 2 and 3
196 reflected the epidemiology of COVID-19 in Malawi (Supplementary Figure 1). Overall, 89.5% of
197 patients survived to hospital discharge (per wave numbers can be seen in Table 1).

198
199 The sequencing laboratory received viral material from 161 of 314 participants. RT-PCR Ct
200 values were available for 156 cases. There was no difference between Ct values from the
201 different waves (Supplementary Figure 2, Kruskal-Wallis test P-value 0.24). There was no
202 significant difference between Ct values from patients who were HIV positive, HIV negative, or
203 whose HIV status was unknown (Supplementary Figure 3, Kruskal-Wallis test P-value = 0.22),
204 although measures of the degree of immunosuppression were unavailable.

205
206 We sequenced all samples with a Ct below 27 (this cut-off was selected based on
207 Supplementary Figure 4), and as many samples with a Ct above 27 as sequencing capacity
208 allowed. Of the 161 cases for which we received viral material, we sequenced 126 samples from

209 126 patients and obtained 55 genomes with greater than 70% coverage at 20x depth
210 (Supplementary Table 2). Low coverage of the genome (<70%) was associated with low viral
211 load (i.e., high Ct). This was true for both ARTIC v3 and UNZA tiling PCR primer sets (Figure 1).
212 Overall, the median Ct value of samples with <70% coverage at 20x depth was 32.0, compared
213 with a Ct 25.9 for samples with \geq 70% coverage (Supplementary Tables 2 & 3).
214




215
216 Figure 1: Relationship between PCR Ct value and the percentage of the SARS-CoV-2 reference
217 genome covered to at least 20x depth. The number at the top of each column is the number of
218 samples for the two protocols in each bin of the box plot.

219
220 We observed three lineages among the 11 SARS-CoV-2 samples from wave 1 (Figure 2,
221 Supplementary Table 2), with the most frequently identified pangolin lineage being B.1 (n=8),
222 followed by B.1.1 (n=2) and B.1.1.448 (n=1). All 6 samples from wave 2 were VOC Beta (exact

223 binomial 95% CI of the estimate in the untested population = 54-100%) and 96% (25/26) of
224 samples from wave 3 were VOC Delta (95% CI 80-100%) (Figure 2). One sample received at the
225 beginning of June 2021 was VOC Beta. We observed seven pangolin lineages among the 25 VOC
226 Delta samples sequenced during wave 3; AY.75.1 (n=11), B.1.617.2 (n=8), AY.75 (n=2) and 1
227 each of AY.50, AY.59, AY.122 and AY.72 (Supplementary Figure 5). Of the 12 successfully
228 sequenced samples from wave 4, 100% (95% CI 73.5-100%) were Omicron VOC. Eleven of
229 twelve were BA.1 with the remaining sample belonging to BA.2. The BA.2 sample came from a
230 patient enrolled in February 2022. Due to low numbers of successfully sequenced isolates
231 during the second wave, we also obtained the genotype of samples from Malawi submitted to
232 GISAID during this time, for which explicit permission could be obtained for re-use from the
233 data depositor; Beta VOC accounted for 100 of the 104 (96%, 95% CI: 90-98%) SARS-CoV-2
234 genomes from Malawi in GISAID which were sampled.

235

236



237

238 Figure 2: The monthly number of each lineage or VOC identified in patients in our cohort.

239

240

241 Clinical Characteristics

242 There were no significant differences in sex or median age between participants between
243 waves (Table 1), however, there was a significant reduction ($p < 0.001$) in time from symptom
244 onset to presentation in Delta (median two days [IQR: 1-5]) and Omicron waves (median two
245 days [IQR: 0-4]) compared to the B.1 (median five days [IQR: 2-8]) or Beta waves (median four
246 days [IQR: 2-9]). There was a lower percentage of patients with cardiac disease (30.0% and
247 23.4% vs 4.1% vs 5.3%, $P < 0.001$) and diabetes (40% vs 19.2% vs 17.5% vs 6.7% $p < 0.001$) in
248 later waves. There was a significant reduction in the numbers of patients requiring oxygen at
249 enrolment during the Omicron wave, with the highest proportion during Delta wave (50% vs
250 58.5% vs 63.9% vs 22.7% $p < 0.001$). Similarly, fewer patients were given steroids during
251 Omicron wave, with the highest numbers receiving steroids in Delta wave (60.4% vs 59.6% vs
252 84.5% vs 38.7% $p < 0.001$). Overall, few patients were vaccinated; in this cohort 21/97 (21.7%)
253 Delta wave participants and 15/75 (20%) Omicron wave participants had received at least one
254 dose of any vaccine. For both unvaccinated and vaccinated groups survival was just under 90%
255 ($p = 0.9$).

256
257 Univariable logistic regression analysis demonstrated that age ≥ 70 (OR 7.21 CI: 1.48-35.07),
258 respiratory rate ≥ 30 (OR 14.87 CI: 3.09 – 71.71) and $SpO_2 \leq 87\%$ (OR 15.4 CI: 5.66– 41.93) were
259 associated with mortality, although with wide confidence intervals (Table 2). Multivariable
260 analysis showed a statistically significant increase in case fatality rate in the whole cohort
261 during the Delta wave (OR 4.99 CI 1.00-25.02) (Table 2). However, the likelihood ratio test for
262 the presence or absence of wave within the model was not significant ($Chi^2 = 5.91$, $p = 0.116$).

263 Therefore, these exploratory findings within our limited cohort should not be overinterpreted.
264 HIV infection; presence of co-morbidities; days from symptoms to admission; and respiratory
265 rate were not associated with survival within the multivariable model. We conducted an
266 exploratory sensitivity analysis including only participants who required oxygen at study
267 enrolment as a marker of disease severity (n=157, of whom 26 [16.6%] died).
268 This demonstrated that admission during Delta wave was independently associated with
269 mortality within a multivariable analysis (OR 13.91 [CI: 1.56-125.06, p=0.018) (Supplementary
270 Table 4).

271 Table 1: Comparison of the demographic and clinical characteristics of COVID patients enrolled
 272 in ISARIC during three waves. UVA: Universal Vital Assessment score (16) LOS: length of stay. TB
 273 positivity was defined according to presence of positive urinary LAM, GeneXpert or sputum test
 274 during hospital admission. Diabetes and Cardiac disease status ascertained from patient history
 275 and medical notes. # Proportion (%) positivity calculated using the denominator for individual
 276 variables (unknown status classified as missing data) and compared using the Fisher's exact
 277 test. §: Median and IQR were compared using the Kruskal-Wallis test
 278

	W1 - "B1" (n=48)	W2 - Beta (n=94)	W3 - Delta (n=97)	W4 - Omicron (n=75)	P value
Female [§]	31.3% (15)	41.5% (39)	28.9% (28)	36.0% (27)	0.302
Age [§]	52 (43 – 64)	46 (37 – 58)	50 (38 – 63)	42 (34 – 58)	0.132
Days from symptoms to admission [§]	5 (2 – 8)	4 (2 – 9)	2 (1 – 5)	2 (0 – 4)	<0.001
Days from admission to sample [§]	4 (2 – 5)	3 (2 – 7)	3 (2 – 5)	3 (2 – 5)	0.725
HIV positive	22.9% (11)	29.8% (28)	26.8% (26)	36.0% (27)	0.422
TB positive	2.1% (1)	1.1% (1)	1.0% (1)	1.3% (1)	1.000
Malaria positive	4.2% (2)	2.1% (2)	1.0% (1)	0.0% (0)	0.274
Cardiac disease	30.0% (13)	23.4% (22)	4.1% (4)	5.3% (4)	<0.001
Diabetes	40.0% (18)	19.2% (18)	17.5% (17)	6.7% (5)	<0.001
Oxygen on enrolment	50.0% (23)	58.5% (55)	63.9% (62)	22.7% (17)	<0.001
UVA score [§]	2 (0 – 4)	2 (0 – 3)	2 (0 – 4)	0 (0 – 2)	0.001
Beta-lactam antibiotic	81.3% (39)	68.1% (64)	82.5% (80)	73.3% (55)	0.096
Steroids	60.4% (29)	59.6% (56)	84.5% (82)	38.7% (29)	<0.001
Survival to discharge	91.7% (44)	90.4% (85)	83.5% (81)	94.7% (71)	0.118
Survivor LOS [§]	8 (6 – 18)	8 (4 – 16)	8 (6 – 11)	7 (4 – 13)	0.368
≥1 Vaccine	0% (0)	0% (0)	21.7% (21)	20.0% (15)	<0.001

279

280

281 Table 2: Clinical factors associated with mortality for SARS-CoV-2 PCR confirmed patients
 282 admitted to hospital with severe acute respiratory infection. Univariable and multivariable
 283 logistic regression analysis with all pre-specified parameters included within the final
 284 multivariable model. Final multivariable model: n=226, $\chi^2 = 62.80$, Pseudo $R^2 = 0.363$.

Variable	Univariate			Multivariate		
	Odds ratio	P value	Confidence Interval	Odds ratio	P value	Confidence Interval
Wave						
2	1.16	0.808	0.34 – 4.00	1.38	0.686	0.29 – 6.51
3	2.17	0.188	0.68 – 6.90	4.99	0.050	1.00 – 25.02
4	0.62	0.514	0.15 – 2.61	2.24	0.392	0.35 – 14.16
Vaccinated	1.07	0.900	0.35 – 3.25	0.92	0.916	0.21 – 4.10
Age						
30-39	0.66	0.679	0.09 – 4.85	0.25	0.262	0.02 – 2.83
40-49	3.22	0.145	0.67 – 15.51	1.54	0.627	0.27 – 8.86
50-59	1.38	0.717	0.24 – 7.93	0.51	0.559	0.05 – 4.85
60-69	1.90	0.473	0.33 – 10.98	0.76	0.795	0.09 – 6.31
≥70	7.21	0.014	1.48 – 35.07	9.55	0.026	1.31 – 69.77
Male	0.60	0.174	0.29 – 1.25	0.51	0.190	0.19 – 1.39
HIV positive	0.82	0.654	0.33 – 1.99	1.08	0.898	0.32 – 3.65
HIV unknown	1.28	0.573	0.54 – 3.07	0.96	0.946	0.30 – 3.11
Cardiac disease	1.44	0.456	0.56 – 3.71	0.82	0.792	0.19 – 3.51
Diabetes	1.20	0.690	0.49 – 2.91	1.15	0.818	0.35 – 3.83
Symptoms to admission (days)						
4-6	2.64	0.037	1.06 – 6.58	2.56	0.132	0.75 – 8.67
7-9	2.59	0.101	0.84 – 8.06	4.24	0.098	0.77 – 23.49
≥10	2.19	0.127	0.80 – 5.99	2.70	0.160	0.68 – 10.75
Respiratory rate						
20-24	2.18	0.321	0.47 – 10.13	1.28	0.778	0.23 – 7.10
25-29	4.07	0.084	0.83 – 20.02	1.16	0.874	1.78 – 7.62
≥30	14.87	0.001	3.09 – 71.71	5.97	0.067	0.88 – 40.26
SpO2						
93-95	1.39	0.569	0.45 – 4.30	0.74	0.659	0.20 – 2.80
88-92	2.54	0.093	0.86 – 7.53	1.44	0.569	0.41 – 5.01
≤87	15.40	<0.001	5.66 – 41.93	11.22	0.001	2.59 – 48.65

285

286 Discussion

287 Using genomic sequencing we were able to define the viral sub-types or VOCs associated with
288 four distinct waves of patients hospitalised with COVID-19. The first wave was predominantly
289 B.1, all sequenced samples from the second wave were Beta VOC, the sequenced samples from
290 the third wave were predominantly Delta, whilst the samples from the fourth wave were
291 largely Omicron BA.1. Infection with Delta variant was associated with a higher risk of mortality,
292 particularly in patients requiring oxygen during admission. This study reports clinical differences
293 in outcome between SARS-CoV-2 variants in a low-income southern African setting in a
294 population with a high burden of infectious disease, including HIV.

295
296 The increased risk of mortality in this cohort was associated with increased age (≥ 70 years) and
297 low oxygen at recruitment ($\text{SpO}_2 < 87\%$), in line with other cohorts (ISARIC, [24]). While our
298 small sample size necessitates caution in interpretation, there was an increased risk of death
299 associated with Delta VOC, particularly in those patients requiring oxygen. Increased mortality
300 with Delta VOC has been reported elsewhere [13–16], but not consistently in Africa [25], where
301 robust clinical data has not commonly been linked with SARS-CoV-2 sequencing data. Patients
302 with severe disease were managed with oxygen, steroids and beta-lactam antibiotics,
303 consistently applied within the hospital between waves. We did not observe an excess of
304 deaths in people living with HIV, however the sample size was low and we did not assess level
305 of immune-suppression in these patients [26]. Patients admitted during the Omicron wave
306 required less oxygen at enrolment, suggesting they were less unwell at presentation, although

307 overall mortality was not significantly lower. This is consistent with other studies in sub-Saharan
308 Africa where patients admitted with COVID-19 during Omicron waves had comparatively less
309 severe disease [16,27,28]. There is a high burden of HIV and a low SARS-CoV-2 vaccine coverage
310 in Malawi [29], this provides a plausible environment for the emergence of novel VOCs [30–33].
311 It is crucial to identify potential VOCs rapidly and report these internationally. The continuation
312 of in-country genomic surveillance in Malawi is therefore important locally and globally.
313
314 Throughout the study there was no invasive and very limited non-invasive ventilatory support
315 available for COVID-19 patients and no access to newer therapies such as interleukin-6
316 antagonists. Therapeutic options for COVID-19 in high income settings are developing rapidly,
317 with genomic viral sequencing used to guide treatments ([NICE](#)). This study thus highlights
318 significant inequity in availability of globally recommended therapeutics for COVID-19 despite
319 relatively high rates of in-patient mortality. It is unclear from this study whether the reduction
320 in severity seen in the Omicron wave was affected by immunity – either vaccine derived or
321 naturally acquired. Overall, 20.9% of the recruited patients in waves three and four were
322 vaccinated with at least one dose (predominantly Astra-Zeneca ChAdOx1-S and J&J
323 Ad26.COV2.S), which is higher than the background population overall, but similar to rates seen
324 in urban Blantyre (25% at least one dose by Feb 2022, Personal Communication, Blantyre
325 District Health Office). However there were already high rates of sero-positivity amongst blood
326 donors in Malawi with 70% of adults SARS-CoV-2 sero-positive in July 2021 during the Delta
327 wave [34] suggesting high population exposure with naturally acquired immunity.
328

329 A strength of our study is that we carried out sequencing and analysis in Malawi directly linked
330 with robust and systematically collected clinical data. In country analysis allowed us to report
331 our findings to clinical and public health partners rapidly. Vital to our success in establishing
332 sequencing in Malawi was the portability of the MinION sequencer; the public lab protocols
333 (18); bioinformatics software from the scientific community (13); and the infrastructure and
334 funding available to us as an international research institution. The MinION platform has
335 become intergral to outbreak response, as demonstrated for SARS-CoV-2 (19,20), Ebola (21)
336 and Zika (22). However, even with this portable and low-maintenance sequencer (with no
337 service contracts or engineer visits required); experienced molecular biologists and
338 bioinformaticians; and considerable international support, it was still very difficult to establish
339 sequencing capability. In particular, we found it extremely challenging to procure reagents, and
340 this was exacerbated by border closures and travel restrictions. As there is no existing policy
341 framework within Malawi for the integration of sequencing data into public health decision
342 making, the utility of our data to decision makers was limited.

343
344 Our study has several limitations. We produced a relatively small number of sequences. This
345 was partly due to the limited number of patients recruited into the study during each wave but
346 also because patients frequently presented with Ct values too high to generate good quality
347 sequence data. Secondly, our observations are limited to a sample of hospitalised patients in a
348 single centre in the southern region of Malawi. Our relatively low sample size impairs our ability
349 to draw firm conclusions on the association between wave and patient outcome. Finally, we
350 recognize that we may not be capturing the full diversity of SARS-CoV-2 circulating in the

351 community, as our sampling of hospitalised patients represents a considerable bias towards
352 people with severe disease, and there is likely to be significant under ascertainment of cases
353 [34].

354
355 In conclusion, pragmatic clinical research protocols coupled with portable sequencing capacity
356 enabled us to improve our understanding of the clinical characteristics and impact of the
357 multiple waves of COVID-19 pandemic in Malawi. We recommend that funders support the
358 development of capacity in genomic surveillance of agents of communicable disease, focussing
359 their strategies on endemic diseases, which can pivot to pandemics and outbreak scenarios as
360 the need arises. A key part of this is the development of robust networks for the production
361 and distribution of molecular biology reagents, mirroring what is being developed for vaccines,
362 as this would enable a more rapid and sustained response to future pandemics. Challenges and
363 opportunities arising from this work are detailed in Box 1. Data and sample collection was
364 enabled by collaboration with the ISARIC consortium. This enabled us to enrol patients very
365 quickly using tools already developed for pandemic response. We were also able to contribute
366 valuable clinical data from a low income setting to global analyses.

367

368

369

370 Acknowledgments

371 The authors thank all study participants and the staff of the Queen Elizabeth Central Hospital
372 (QECH) for their support and co-operation during the study. We would like to thank all the
373 people mentioned in Supplementary File 1 for sharing their data to GISAID.

374 This work was supported by the UK Foreign, Commonwealth and Development Office and
375 Wellcome grants for SARS-CoV-2 diagnostics [220757/Z/20/Z] and the MLW Core grant
376 [206545/Z/17/Z]. KGB is supported by an NIH-Fogarty fellowship [TW010853]. The study was
377 reported in line with STROBE guidelines.

378 We would like to acknowledge the contribution of the following members of the Blantyre
379 COVID-19 Consortium; Clinical - Wezzie Kalua, Peter Mandala, Barbara Katutula, Rosaleen
380 Ng'oma, Steven Lanken, Jacob Phulusa, Mercy Mkandawire, Sylvester Kaimba, Sharon Nthala,
381 Edna Nsomba, Lucy Keyala, Beatrice Chinoko, Markus Gmeiner, Vella Kaudzu, Bridget Freyne,
382 Todd D. Swarthout and Pui-Ying Iroh Tam. Laboratory - Simon Sichone, Ajisa Ahmadu, Grace
383 Stima, Mazuba Masina, Oscar Kanjewa, Vita Nyasulu, End Chinyama, Allan Zuza, Brigitte Denis,
384 Evance Storey, Nedson Bondera, Danford Matchado, Adams Chande, Arthur Chingota,
385 Chimenya Ntwea, Langford Mkandawire, Chimwemwe Mhango, Agness Lakudzala, Mphatso
386 Chaponda, Percy Mwenechanya, Leonard Mvaya and Dumizulu Tembo. Data and statistics -
387 Marc Y. R. Henrion, James Chirombo, Paul Kambiya, Clemens Masesa & Joel Gondwe.

388

389

390 Conflict of interest statement

391 We have no conflicts of interest to declare.

392 Data availability statement

393 All genome sequences are available in GISAID and INSDC databases – accessions are available in
394 Supplementary Table 2.

395

396

397 References

- 398 1. Brito AF, Semenova E, Dudas G, et al. Global disparities in SARS-CoV-2 genomic
399 surveillance. medRxiv **2021**; :2021.08.21.21262393.
- 400 2. Aborode AT, Hasan MM, Jain S, et al. Impact of poor disease surveillance system on
401 COVID-19 response in africa: Time to rethink and rebuilt. Clinical Epidemiology and Global
402 Health **2021**; 12:100841.
- 403 3. Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-
404 CoV-2 omicron variant in South Africa: a data linkage study. The Lancet **2022**; 399:437–
405 446.
- 406 4. Novel 2019 coronavirus genome - SARS-CoV-2 coronavirus. 2020. Available at:
407 <https://virological.org/t/novel-2019-coronavirus-genome/319>. Accessed 28 October 2021.
- 408 5. CDC. CDC’s Diagnostic Test for COVID-19 Only and Supplies. 2020. Available at:
409 <https://www.cdc.gov/coronavirus/2019-ncov/lab/virus-requests.html>. Accessed 28
410 October 2021.
- 411 6. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19
412 Vaccine. New England Journal of Medicine **2020**; 383:2603–2615.
- 413 7. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2
414 Vaccine. New England Journal of Medicine **2021**; 384:403–416.
- 415 8. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK
416 defined by a novel set of spike mutations - SARS-CoV-2 coronavirus / nCoV-2019 Genomic
417 Epidemiology. 2020. Available at: [https://virological.org/t/preliminary-genomic-
418 characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-
419 spike-mutations/563](https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563). Accessed 28 October 2021.
- 420 9. Tegally H, Wilkinson E, Giovanetti M, et al. Emergence and rapid spread of a new severe
421 acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple
422 spike mutations in South Africa. 2020: 2020.12.21.20248640. Available at:
423 <https://www.medrxiv.org/content/10.1101/2020.12.21.20248640v1>. Accessed 31
424 December 2021.
- 425 10. Why genomic sequencing is crucial in COVID-19 response. Available at:
426 <https://www.afro.who.int/news/why-genomic-sequencing-crucial-covid-19-response>.
427 Accessed 24 January 2022.

- 428 11. Nyasulu JCY, Munthali RJ, Nyondo-Mipando AL, et al. COVID-19 pandemic in Malawi: Did
429 public sociopolitical events gatherings contribute to its first-wave local transmission?
430 *International Journal of Infectious Diseases* **2021**; 106:269–275.
- 431 12. Morton B, Barnes KG, Anscombe C, et al. Distinct clinical and immunological profiles of
432 patients with evidence of SARS-CoV-2 infection in sub-Saharan Africa. *Nat Commun* **2021**;
433 12:3554.
- 434 13. Twohig KA, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance
435 risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a
436 cohort study. *The Lancet Infectious Diseases* **2022**; 22:35–42.
- 437 14. Bager P, Wohlfahrt J, Rasmussen M, Albertsen M, Krause TG. Hospitalisation associated
438 with SARS-CoV-2 delta variant in Denmark. *The Lancet Infectious Diseases* **2021**; 21:1351.
- 439 15. Bast E, Tang F, Dahn J, Palacio A. Increased risk of hospitalisation and death with the delta
440 variant in the USA. *The Lancet Infectious Diseases* **2021**; 21:1629–1630.
- 441 16. Hussey H, Davies M-A, Heekes A, et al. Assessing the clinical severity of the Omicron
442 variant in the Western Cape Province, South Africa, using the diagnostic PCR proxy marker
443 of RdRp target delay to distinguish between Omicron and Delta infections - a survival
444 analysis. *Int J Infect Dis* **2022**; 118:150–154.
- 445 17. Clinical Characterisation Protocol (CCP). Available at: [https://isaric.org/research/covid-19-](https://isaric.org/research/covid-19-clinical-research-resources/clinical-characterisation-protocol-ccp/)
446 [clinical-research-resources/clinical-characterisation-protocol-ccp/](https://isaric.org/research/covid-19-clinical-research-resources/clinical-characterisation-protocol-ccp/). Accessed 28 October
447 2021.
- 448 18. Malawi vaccine roll out: Chakwera first jab at Zomba Covid-19 field hospital, Chilima in
449 Mzuzu - Malawi Nyasa Times - News from Malawi about Malawi. 2021. Available at:
450 [https://www.nyasatimes.com/malawi-vaccine-roll-out-chakwera-first-jab-at-zomba-covid-](https://www.nyasatimes.com/malawi-vaccine-roll-out-chakwera-first-jab-at-zomba-covid-19-field-hospital-chilima-in-mzuzu/)
451 [19-field-hospital-chilima-in-mzuzu/](https://www.nyasatimes.com/malawi-vaccine-roll-out-chakwera-first-jab-at-zomba-covid-19-field-hospital-chilima-in-mzuzu/). Accessed 25 May 2022.
- 452 19. Banda NP, Hara W, Cocker D, et al. First case report of a successfully managed severe
453 COVID-19 infection in Malawi. *Malawi Med J* **2020**; 32:226–228.
- 454 20. Simulundu E, Mupeta F, Chanda-Kapata P, et al. First COVID-19 case in Zambia -
455 Comparative phylogenomic analyses of SARS-CoV-2 detected in African countries. *Int J*
456 *Infect Dis* **2021**; 102:455–459.
- 457 21. ARTIC field bioinformatics pipeline. Available at: [https://github.com/artic-](https://github.com/artic-network/fieldbioinformatics)
458 [network/fieldbioinformatics](https://github.com/artic-network/fieldbioinformatics). Accessed 28 October 2021.
- 459 22. O’Toole Á, Scher E, Underwood A, et al. Assignment of Epidemiological Lineages in an
460 Emerging Pandemic Using the Pangolin Tool. *Virus Evolution* **2021**; :veab064.

- 461 23. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for
462 Statistical Computing, 2021. Available at: <https://www.R-project.org/>.
- 463 24. ISARIC Clinical Characterisation Group, Baillie JK, Baruch J, et al. ISARIC COVID-19 Clinical
464 Data Report issued: 27 March 2022. *Infectious Diseases (except HIV/AIDS)*, 2020. Available
465 at: <http://medrxiv.org/lookup/doi/10.1101/2020.07.17.20155218>. Accessed 25 May 2022.
- 466 25. Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and
467 Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave
468 Compared With Previous Waves. *JAMA* **2022**; 327:583–584.
- 469 26. Danwang C, Noubiap JJ, Robert A, Yombi JC. Outcomes of patients with HIV and COVID-19
470 co-infection: a systematic review and meta-analysis. *AIDS Research and Therapy* **2022**;
471 19:3.
- 472 27. Abdullah F, Myers J, Basu D, et al. Decreased severity of disease during the first global
473 omicron variant covid-19 outbreak in a large hospital in tshwane, south africa. *Int J Infect*
474 *Dis* **2022**; 116:38–42.
- 475 28. Jassat W, Karim SSA, Mudara C, et al. Clinical severity of COVID-19 patients admitted to
476 hospitals during the Omicron wave in South Africa. 2022; :2022.02.22.21268475. Available
477 at: <https://www.medrxiv.org/content/10.1101/2022.02.22.21268475v1>. Accessed 25 May
478 2022.
- 479 29. Malawi marks one year of COVID-19 vaccination, 828, 080 people receive full dose.
480 Available at: [https://www.afro.who.int/countries/malawi/news/malawi-marks-one-year-](https://www.afro.who.int/countries/malawi/news/malawi-marks-one-year-covid-19-vaccination-828-080-people-receive-full-dose)
481 [covid-19-vaccination-828-080-people-receive-full-dose](https://www.afro.who.int/countries/malawi/news/malawi-marks-one-year-covid-19-vaccination-828-080-people-receive-full-dose). Accessed 1 July 2022.
- 482 30. Weigang S, Fuchs J, Zimmer G, et al. Within-host evolution of SARS-CoV-2 in an
483 immunosuppressed COVID-19 patient as a source of immune escape variants. *Nat*
484 *Commun* **2021**; 12:6405.
- 485 31. Karim F, Moosa MYS, Gosnell BI, et al. Persistent SARS-CoV-2 infection and intra-host
486 evolution in association with advanced HIV infection. 2021; :2021.06.03.21258228.
487 Available at: <https://www.medrxiv.org/content/10.1101/2021.06.03.21258228v1>.
488 Accessed 9 May 2022.
- 489 32. Cele S, Karim F, Lustig G, et al. SARS-CoV-2 prolonged infection during advanced HIV
490 disease evolves extensive immune escape. *Cell Host & Microbe* **2022**; 30:154-162.e5.
- 491 33. Wilkinson SA, Richter A, Casey A, et al. Recurrent SARS-CoV-2 Mutations in
492 Immunodeficient Patients. 2022; :2022.03.02.22271697. Available at:
493 <https://www.medrxiv.org/content/10.1101/2022.03.02.22271697v1>. Accessed 25 May
494 2022.

- 495 34. Mandolo J, Msefula J, Henrion MYR, et al. SARS-CoV-2 exposure in Malawian blood
496 donors: an analysis of seroprevalence and variant dynamics between January 2020 and
497 July 2021. BMC Medicine **2021**; 19:303.

498